The findings reviewed by GME stated that the Global Insomnia Therapeutics Marketwill expand with a CAGR value of 10.2% from 2021 to 2026. The insomnia market is estimated to rise over the projected period, attributed to high insomnia incidence and need for innovative treatments, the advent of medicines with minimal side effects, & stressful job & shift work. Furthermore, throughout the predicted period an increase in demand for over-the-counter sleep aids is likely to provide substantial potential opportunities in the industry.
Browse 151 Market Data Tables and 111 Figures spread through 189 Pages and in-depth TOC on "Global Insomnia Therapeutics Market - Forecast to 2026"
https://www.globalmarketestimates.com/market-report/global-insomnia-therapeutics-market-3230
By Treatment Type [Devices, Drugs (Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonists, Melatonin Antagonists)], By Sales Channel (Prescription, Over-the-Counter (OTC)), By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa); End-User Landscape, Company Market Share Analysis & Competitor Analysis
Key Market Insights
- Insomnia is more prevalent in adults than in the young, owing to pharmacological side effects related to the diagnosis of chronic illnesses.
- The market expansion is fueled by rising health awareness, which leads to effective insomnia therapy, as well as increasing healthcare systems.
- The industry is predicted to rise with the advancement of technological developments and the launch of medical equipment.
- In addition, over the projection period, demand is likely to be boosted by constantly improving healthcare reimbursement policies in the APAC region
- Vanda Pharmaceuticals;Takeda Pharmaceutical Company Ltd.; Inc.; Paratek Pharmaceuticals Inc.; Pfizer Inc.; Merck & Co., Teva Pharmaceutical Industries Ltd.; Sumitomo Dainippon Pharma Co., Ltd; Mylan N.V.; Ebb Therapeutics, Sanofi; and others, are major players of insomnia therapeutics market.
Browse the Report @https://www.globalmarketestimates.com/market-report/global-insomnia-therapeutics-market-3230
Treatment Type Outlook (Revenue, USD Billion, 2021-2026)
- Drugs
- Benzodiazepines
- Nonbenzodiazepines
- Antidepressants
- Orexin antagonists
- Melatonin antagonists
- Others
- Devices
Sales channel Outlook (Revenue, USD Billion, 2021-2026)
- Prescription
- Over-the-Counter (OTC)
Regional Outlook (Revenue, USD Billion, 2021-2026)
North America
- The U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Rest of APAC
Central & South America
- Brazil
- Argentina
- Rest of CSA
Middle East & Africa
- Saudi Arabia
- UAE
- Rest of MEA
Contact: Tracy Simon
Email address: tracy.simon@globalmarketestimates.com
Phone Number: +16026667238
Website: https://www.globalmarketestimates.com/
Check our Latest Blogs: https://www.globalmarketestimates.com/blog-posts.php
0 Comments